正在加载公司
Attovia Therapeutics, Inc.
ATTO · Nasdaq · Healthcare · Biotechnology
US$18.12+2.8%9月29日 收盘
- 1M
- -12.5%
- 6M
- +3,707.5%
- 1Y
- +3,707.5%
- 5Y
- -37.5%
ATTO · Nasdaq · Healthcare · Biotechnology
US$18.12+2.8%9月29日 收盘
取自公司自己的 8-K 文件。
暂无 Attovia Therapeutics, Inc. 的业绩电话会文字记录。
“Following the successful completion of our upsized IPO, Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating milestones,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在收盘后或开盘前发布，因此这里的变动是随后的那个交易日。
Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates. Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Attovia Therapeutics, Inc. 于 2026年9月2日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。